Cart
sales@molnova.com
Sotatercept
CAS No. 1001080-50-7
Sotatercept( —— )
Catalog No. M36791 CAS No. 1001080-50-7
Sotatercept (ACE-011) is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein and inhibitor of activin signaling.Sotatercept can be used in the study of pulmonary arterial hypertension.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 880 | Get Quote |
|
| 5MG | 1406 | Get Quote |
|
| 10MG | 2271 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSotatercept
-
NoteResearch use only, not for human use.
-
Brief DescriptionSotatercept (ACE-011) is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein and inhibitor of activin signaling.Sotatercept can be used in the study of pulmonary arterial hypertension.
-
DescriptionSotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTGF-beta/Smad
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1001080-50-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215. ?
molnova catalog
related products
-
N-Formyl-Met-Leu-Phe...
N-Formyl-Met-Leu-Phe-Lys (fMLFK) is a peptide, acts as a potent and selective agonist of FPR1, with EC50s of 3.5 nM, 6.7 μM and 0.88 μM for FPR1, FPR2 and FPR2-D2817.32G, respectively.
-
Saposin C22
Saposin C22
-
NLS-StAx-h
Wnt inhibitor (IC50 = 1.4 μM). Stapled peptide inhibitor of oncogenic Wnt signaling. Inhibits β-catenin-transcription factor interactions. Inhibits proliferation and migration of colorectal cancer cells. Cell permeable.
